Ottawa – The Canada Border Services Agency (CBSA) reminds travellers that it can be extra busy at the border during March Break. Every day, the CBSA works hard to protect Canadians, support the economy and ensure the safe and efficient movement of people and goods across the border. In 2024, we welcomed over 93.4 million travellers, stopped over 34,400 kg of illegal drugs …
Canada’s largest investment in improving youth mental health
British Columbia – When young people face mental health challenges, having the right support can make a meaningful difference for them, their families, and communities. The Youth Mental Health Fund, Canada’s largest investment in youth mental health, will improve and enhance access to compassionate care that meets youth where they are at. By supporting community organizations to expand services for …
Healthy Babies-What Information is Available
Ottawa – The aim of Health Canada is to improve the health of all Canadians. A healthy pregnancy and birth, followed by a child’s healthy growth and development during the first years of life, will have long-lasting benefits. Health Canada provides information to parents on specific topics in order to reduce the risk of injury and illness and to promote …
Canada takes further action to address fentanyl precursor chemicals
Ottawa – We are accelerating Canada’s work to detect, disrupt, and dismantle the fentanyl trade. Illegal drugs are having a devastating impact on people and communities, including creating security challenges associated with their illegal production, importation, trafficking, and related crimes. Health Canada plays a critical role in supporting Canadian law and border enforcement in their activities to disrupt the global …
Increasing oversight for precursor chemicals, drug equipment
Ottawa – The Government of Canada is concerned with the impact of fentanyl, and other illegal synthetic drugs on the overdose crisis and on public safety, including security challenges associated with their illegal production, importation, trafficking, and related crimes. Health Canada plays a critical role in supporting Canadian law and border enforcement in their activities to counter the global synthetic …
Drugs for Rare Diseases – New Brunswick Agreement
New Brunswick – Governments of Canada and the province of New Brunswick signed the National Strategy for Drugs for Rare Disease (DRD) agreement to invest over $32 million over three years to improve access to new drugs for rare diseases for New Brunswick residents and to support enhanced access to existing drugs, early diagnosis, and screening for rare diseases. In March …
Amendments to Hazardous Products Regulations
Ottawa – Some time back Health Canada published amendments to the Hazardous Products Regulations (HPR) in the Canada Gazette, Part II, to align with the 7th revised edition, and certain provisions of the 8th revised edition, of the Globally Harmonized System of Classification and Labelling of Chemicals (GHS). The amendments came into force on December 15, 2022. Canada Gazette, Part II, Volume 157, …
Trulicity now indicated as adjunct to diet, exercise
TORONTO – In recent past, Health Canada approved Trulicity® (dulaglutide) to reduce the risk of non-fatal stroke in adults with type 2 diabetes mellitus who have multiple cardiovascular risk factors or established cardiovascular disease, as an adjunct to diet, exercise, and standard of care therapy. This decision makes Eli Lilly and Company’s Trulicity the first and only GLP1 receptor agonist (RA) approved …
Protect yourself from bug bites
Ottawa – Health Canada always reminds Canadians to protect themselves from bug bites by safely using bug spray and other insect repellents. Bug bites can cause a number of health problems from itchiness and irritation, to potentially serious diseases. Personal insect repellents can help protect you from mosquito, blackfly and tick bites, but it’s important to remember that they should …
Lilly’s tirzepatide is superior to Wegovy in head-to-head trial
TORONTO– Eli Lilly Canada today announced topline results from the SURMOUNT-5 Phase 3b open-label randomized clinical trial. Tirzepatide provided a 47% greater relative weight loss compared to Wegovy® (semaglutide). On average, tirzepatide led to a superior weight loss of 20.2% compared to 13.7% with Wegovy. At 72 weeks, tirzepatide was superior to Wegovy on both the primary endpoint and all five …